Both of the mRNA vaccines available in the US are highly effective against severe COVID-19, but recent studies suggest that Moderna’s elicits a stronger immune response and might be better at preventing breakthrough infections.
The Scientist Creative Services Team in collaboration with 10x Genomics | 1 min read
Paul Thomas from St. Jude Children’s Research Hospital will discuss how he used single cell and spatial transcriptomics to discover the underlying mechanism of an inflammatory immune response in the lungs.
A review of hundreds of cases finds that only a minority of patients noted being sick with a coronavirus infection prior to developing the severe inflammatory condition.
Rollouts of the shot have ground to a halt following reports of blood clots, but health authorities say that these fears are unfounded and vaccination programs should continue.
Stronger interferon production, greater T cell activation, and increased susceptibility to autoimmunity are just some of the ways that females seem to differ from males.
Males and females show differences in gene expression, cell activation, and antibody production in response to some viral infections, but whether these influence COVID-19 outcomes is still unclear.
Death rates among blood cancer patients who contract COVID-19 are higher than for those with other cancers, pointing to impaired immunity that makes it hard to overcome the virus.
With many millions of people waiting several weeks to receive a second COVID-19 vaccine dose in some countries, experts consider the possibility that SARS-CoV-2 could evolve vaccine resistance.
Madhvi Menon will discuss immune profiling of COVID-19 patients and Jyoti Phatak-Sheldon will highlight the use of RNAscope in situ hybridization in SARS-CoV-2 research.
Half a year after infection, people who had recovered from COVID-19 had robust antibodies, along with traces of the virus in their gut, which may drive long-lasting immunity.